KR101513240B1 - A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds - Google Patents
A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds Download PDFInfo
- Publication number
- KR101513240B1 KR101513240B1 KR1020130068969A KR20130068969A KR101513240B1 KR 101513240 B1 KR101513240 B1 KR 101513240B1 KR 1020130068969 A KR1020130068969 A KR 1020130068969A KR 20130068969 A KR20130068969 A KR 20130068969A KR 101513240 B1 KR101513240 B1 KR 101513240B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- mixture
- extract
- herbal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 239000000284 extract Substances 0.000 title claims abstract description 61
- 238000011084 recovery Methods 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 230000036541 health Effects 0.000 claims abstract description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011593 sulfur Substances 0.000 claims abstract description 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 241000411851 herbal medicine Species 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241000287828 Gallus gallus Species 0.000 claims description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 244000273928 Zingiber officinale Species 0.000 claims description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 10
- 235000008397 ginger Nutrition 0.000 claims description 10
- 241000700199 Cavia porcellus Species 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 241001474374 Blennius Species 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 229940010454 licorice Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 claims 4
- 240000006394 Sorghum bicolor Species 0.000 claims 2
- 244000126002 Ziziphus vulgaris Species 0.000 claims 2
- 229930003633 citronellal Natural products 0.000 claims 2
- 235000000983 citronellal Nutrition 0.000 claims 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000007659 motor function Effects 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 235000013330 chicken meat Nutrition 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 240000004371 Panax ginseng Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 241001672694 Citrus reticulata Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000005499 Sasa Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 210000003056 antler Anatomy 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000010865 sewage Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- -1 wine Chemical class 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000759833 Cornus officinalis Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 2
- 240000008866 Ziziphus nummularia Species 0.000 description 2
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 235000019997 soju Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000008955 Dioscorea japonica Species 0.000 description 1
- 235000005251 Dioscorea japonica Nutrition 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000092659 Pleuropterus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940111205 diastase Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 201000009863 inflammatory diarrhea Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000003817 vacuum liquid chromatography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물을 함유하는 조성물에 관한 것으로서, 상기 생약혼합물의 추출물을 함유하는 조성물은 운동기능의 유지능력, 피로회복 개선 효과가 우수하여, 수험생, 직장인, 회복기 환자들의 피로회복용 조성물 또는 건강기능식품으로 용이하게 사용 가능하다. The present invention relates to a composition containing an extract of a crude drug mixture comprising Hassuo, Manzan, Sansui, Sulfur and Sulfur, wherein the composition containing the extract of the crude drug mixture is excellent in the ability to maintain a motor function and to improve fatigue recovery , A candidate, a worker, a convalescent patient in a recovery period, or a health functional food.
Description
본 발명은 생약혼합물을 유효성분으로 함유하는 피로회복용 조성물에 관한 것으로서, 자세하게는, 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물을 유효성분으로 함유하는 피로회복용 조성물에 관한 것이다. TECHNICAL FIELD The present invention relates to a composition containing a herbal medicine as an active ingredient, and more particularly, to a composition containing a herbal composition containing an extract of a herbal medicine mixture containing Sasa, Mandarin, Sanshu Oil,
오늘날 고도의 산업화 사회로 접어들면서 사회생활 등에 따른 스트레스가 증가하고 불규칙한 식습관, 잦은 음주문화 등으로 피로가 축적되어 만성피로에 시달리는 사람들의 수가 증가하였다. 의학적으로 스트레스, 우울증, 불안장애 등과 같은 정신적 문제가 이러한 피로 증상의 원인 중 약 50%를 차지하며, 신체적 질환으로는 당뇨병, 갑상선질환, 만성호흡기질환, 빈혈, 결핵, 간염, 신장질환(腎臟疾患)이나 암 등에 의해서도 만성적 피로감을 느낄 수 있다. 이와 같은 질환이 없는 것이 판명되면 만성피로증후군(chronic fatigue syndrome)으로 진단할 수 있다. 만성피로증후군은 쉽게 피곤하고 지치며 몸이 나른해지는 등의 피로 증세가 6개월 이상 만성적으로 지속하는 증세로서, 확실한 원인은 밝혀져 있지 않고, 평소 건강한 사람에게서 감기나 몸살 기운이 있다가 이런 피로가 나타난다. Today, as we move into a highly industrialized society, the number of people suffering from chronic fatigue has increased due to increased stress due to social life, accumulation of fatigue due to irregular eating habits and frequent drinking culture. Mental problems such as medical stress, depression, and anxiety disorder account for about 50% of the causes of these fatigue symptoms. Physical diseases include diabetes, thyroid disease, chronic respiratory disease, anemia, tuberculosis, hepatitis, kidney disease ) Or cancer can also cause chronic fatigue. Chronic fatigue syndrome (chronic fatigue syndrome) can be diagnosed if it is found that there is no such disease. Chronic Fatigue Syndrome is a condition in which the fatigue symptoms, such as easily tired and tired, the fatigue of the body is chronic, lasting more than six months, and the cause of the fatigue is unknown, and a fatigue occurs when there is a cold or body fatness in a normal healthy person .
이러한 피로 증상은 만병의 근원이자 비만 또는 지나친 체중저하를 유도하기도 하여 건강을 망치는 주범이다.These fatigue symptoms are a source of panic disease and also lead to obesity or excessive weight loss, leading to health problems.
하수오(何首烏, Pleuropterus multflorus)는 중국 원산이며 약용식물로 가꾸고 있다. 뿌리줄기가 땅속으로 벋으면서 군데군데 고구마같이 굵은 덩이뿌리가 생긴다. 붉은빛을 띤 갈색 덩이뿌리를 한방에서 하수오라고 하며 강장제, 강정제, 완하제로 사용한다. 잎은 나물로 하며 생잎을 곪은 데 붙여서 고름을 흡수시킨다. 이와 비슷한 것에는 나도하수오(P. cilinervis)가 있으며, 높은산의 능선과 계곡에서 자란다.Hwaseo ( Pleuropterus multflorus ) is a Chinese origin and is being cultivated as a medicinal plant. Root stalks are falling into the ground, and thick roots like sweet potatoes are formed. Reddish brown roots are called "Hashuo" in one room. They are used as tonic, laxative and laxative. Leaves are herbs and attached to the roasted leaves to absorb pus. Similar to me, I also have P. cilinervis , which grows in ridges and valleys of high mountains.
만삼(蔓蔘, Codonopsis pilosula)은 뿌리가 도라지 모양이며 생약으로는 이 뿌리를 이용한다. 만삼의 뿌리를 당삼(黨蔘) 또는 삼이라고 하며 거담제로 사용하거나 식용한다. Ginseng (蔘 蔘, Codonopsis pilosula ) has a bell-shaped root and uses this root as a crude drug. The roots of manchans are called ginseng (蔘 蔘) or ginseng, and they are used as expectorants or edible.
산수유(山茱萸)는 층층나무과 낙엽교목인 산수유나무(Cornus officinalis)의 열매로서, 타원형의 핵과(核果)로서 처음에는 녹색이었다가 8~10월에 붉게 익는다. 종자는 긴 타원형이며, 능선이 있다. 약간의 단맛과 함께 떫고 강한 신맛이 난다. 10월 중순의 상강(霜降) 이후에 수확하는데, 육질과 씨앗을 분리하여 육질은 술과 차 및 한약의 재료로 사용한다. 과육(果肉)에는 코르닌(cornin), 모로니사이드(Morroniside), 로가닌(Loganin), 타닌(tannin), 사포닌(Saponin) 등의 배당체와 포도주산, 사과산, 주석산 등의 유기산이 함유되어 있고, 그밖에 비타민 A와 다량의 당(糖)도 포함되어 있다. 종자에는 팔미틴산, 올레인산, 리놀산 등이 함유되어 있다. 성분 중 코르닌은 부교감신경의 흥분작용이 있는 것으로 알려져 있다. 예로부터 한방에서는 과육을 약용하였다. 동의보감, 향약집성방 등에 의하면 강음(强陰), 신정(腎精)과 신기(腎氣)보강, 수렴 등의 효능이 있다고 한다. 두통, 이명(耳鳴), 해수병, 해열, 월경과다 등에 약재로 쓰이며 식은땀, 야뇨증 등의 민간요법에도 사용된다. 차나 술로도 장복하며, 지한(止汗), 보음(補陰) 등의 효과가 있다. 산수유나무는 한국, 중국 등이 원산으로, 한국의 중부 이남에서 심는다. 국내에서는 전라남도 구례군 산동면과 경기도 이천시 백사면 일원, 경상북도 의성군 등에서 특산품으로 매년 출하하고 있다. Cornus officinalis is a fruit of a deer and a deciduous tree, Cornus officinalis. It is an oval nucleus and initially green, but ripens in August and October. Seeds are long oval and have ridges. It has a bitter sweetness and strong acidity. It is harvested after the frost fall in mid-October. The flesh is separated from the seeds and the meat is used as a material for sake, tea and Chinese medicine. The pulp contains the glycosides such as cornin, morroniside, loganin, tannin and saponin and organic acids such as wine, malic and tartaric acid. In addition, it contains vitamin A and a large amount of sugars. Seeds include palmitic acid, oleic acid, linoleic acid, and the like. Among the components, cornin is known to have an excitatory action of parasympathetic nerves. From the past, the pulp was weakened in one batch. It is said that it has efficacy such as strengthening of 阴 阴, 肾 精 and 肾气 reinforcement, convergence according to Dongbibogam, It is used for medicines such as headache, tinnitus, blood circulation, fever, and menstrual hyperactivity. It is also used for folk remedies such as cold sweat and enuresis. It can also be used as a tea or a drink, and has effects such as stopping sweat and consonant. Sansui is native to Korea and China, and is planted in the middle of South Korea. In Korea, Shandong, Gyeonggi Province, Gyeonggi Province, Gyeonggi Province, and Gyeongsangbukdo, Yusung Gun, and other local products are shipped every year.
숙지황(熟地黃)은 지황(地黃)의 뿌리를 쪄서 말린 한약재이며, 지황은 현삼과에 딸린 여러해살이 약용식물로 그 뿌리를 한방에서 약재로 쓰는데, 날것을 생지황, 말린 것을 건지황이라 하며, 숙지황 중 특히 술에 담갔다가 쪄서 말리기를 9번 되풀이하여 만든 것은 구지황이라 하여 그 약효를 으뜸으로 친다. 맛은 달면서도 쓴맛이 돌고 따뜻한 성질이 있어 혈을 보(補)하고 정(精:생명이 발생하고 활동하는 데 기본이 되는 물질)을 보충해서 허리와 무릎이 시리고 아픈 증상이나 월경이상, 어지럼증 등을 치료하고 머리를 검게 하는 효능이 있다. 숙지황은 사물탕(四物湯)의 주요 약재이며 각종 만성병 중 몸이 허약하여 나타나는 내열(內熱), 인후건조(咽喉乾燥), 갈증 등의 증상에 쓰인다. 사물탕은 여성의 출산 후나 월경 등으로 인한 과다출혈, 허약, 어지럼증 등에 널리 쓰인다. 예로부터 허담(虛痰)을 치료하는 데 효과가 있어 차로 달여 마셨으며, 기침과 천식에 복령(茯笭), 반하(半夏) 등과 배합하여 사용하였다. 이밖에도 돼지고기를 삶은 국물과 함께 복용하면 습관성 변비에 효과가 있다. 영양분이 많고 기름기가 있어 장기간 복용하면 소화장애를 일으켜 설사, 복창(腹脹) 등 부작용이 생긴다. 그러므로 입맛이 없고 소화가 안되며 설사를 하는 환자에게는 신중하게 사용해야 한다. 熟地 黄 (熟地黄) is a Chinese medicine dried by steaming the roots of geohang (黄黄), and is a medicinal plant of perennial herb attached to the ginseng root. Its root is used as a medicinal material in one room. Especially, it is said that it is made by repeating 9 times of steaming and drying after soaking in alcohol. It has a bitter taste with a bitter taste, but it has a warm temperament, and it replenishes its blood and replenishes its essence (a substance that is fundamental to life and activity). It causes back and knee pain, sore symptoms, menstrual disorder, dizziness It has the efficacy to cure the head and darken the head. Sukjipang is the main medicinal material of Sangmangtang, and it is used for symptoms such as inner heat, sore throat, and thirst which are manifested by weakness of various chronic diseases. Samtang is widely used for excessive bleeding, weakness and dizziness caused by women's birth or menstruation. It has been effective for treating Huhdam (虛 痰) for a long time. It was drunk on tea for a few months. It was used in combination with cough and asthma, 茯 笭 and half summer. In addition, boiled pork with broth is effective when taking habitual constipation. There is a lot of nutrients and greasy, and when taken for a long time causes digestive disorders, diarrhea, recurrence (腹 unction) and other side effects occur. Therefore, it should be used with caution in patients with no appetite, no digestion, and diarrhea.
산약(山藥)은 마과(科: Dioscoreaceae)에 속한 덩굴성 참마(Dioscorea japonica) 또는 마(Disocorea batatas)의 덩이뿌리이다. 전분, 점액질, 단백질, 지방, 아르지닌콜린 등과 디아스타제를 함유하고 있다. 냄새가 거의 없으며 맛은 달고 성질은 따듯하다. 효능으로 식욕이 감퇴하며 원기가 부족할 때는 백출(白朮), 연밥, 인삼 등과 함께 달여 복용하며, 잠잘 때 식은 땀을 흘릴 경우(盜汗) 숙지황, 산수유 등과 달여 복용한다. 산약은 비기능을 높여 권태감, 무력감, 음식감소, 설사 등을 다스리며 폐음을 보해 해수, 천식, 가래를 없애고, 소갈증, 허리와 무릎 시린 증상, 유정, 조루증, 소변 자주 보는 증상, 신체허약과 빈혈, 사지마비동통 등에 사용한다. 약리작용으로 장관활동자극, 혈당강하, 항노화작용 등이 보고되었다. 몸이 마르고 원기가 부족하는 등의 허한 증상을 보일 때는 인삼, 패모(貝母), 복령(茯??), 행인(杏仁) 등을 배합하여 달여 복용하면 좋다. 당뇨병에도 매일 달여 장기간 차 대신 복용하면 효과가 있으나, 염증성 설사를 하거나 대변이 굳을 때는 복용을 중지한다. 그 밖에도 너무 많이 복용하면 기체(氣滯)를 일으킬 수도 있다. Mountain medicine is the root of the root of the mosquito (Dioscorea japonica) or horse (Disocorea batatas) belonging to the family Dioscoreaceae. Starch, mucus, protein, fat, arginine choline, and diastase. There is almost no smell, the taste is sweet and the quality is warm. When the appetite is diminished by the effect, when it is lacking refreshing, it is taken in the month with white puffer, rice, ginseng, etc., and when you sweat when you sleep, Asthma, asthma, and sputum are removed, and symptoms such as petechiae, back and knee pain, wells, premature ejaculation, frequent symptoms of urination, weakness of the body and anemia, It is used for limb paralysis. The pharmacological action stimulated intestinal activity, decreased blood sugar, and anti-aging activity. When you see symptoms such as body dryness and lack of refreshing, it is good to mix it with ginseng, mackerel, bokyeong (茯 ??), and passenger (杏仁). Diabetes mellitus every day, taking a long-term tea instead of taking effect, but if you have inflammatory diarrhea or when the stool is stopped, stop taking. In addition, taking too much can cause gas (气 滯).
한편, 각종 생약을 이용한 피로회복용 건강기능식품들에 대한 선호도가 높아지고 있으나, 그 효능과 효과가 과학적으로 입증되지 못한 채 생약재 기반의 약재들이 무분별하게 남용 또는 오용되고 있다. On the other hand, although the preference for health food products using various herbal medicines is increasing, its efficacy and effectiveness have not been scientifically proved, and medicines based on herbal medicines have been abused or misused abusively.
이에 본 발명자들은 피로회복제에 대한 연구를 하던 중, 상기 하수오, 만삼, 산수유, 숙지황 및 산약을 함유하는 생약혼합물의 추출물이 피로회복 효과가 있음을 확인하여 본 발명을 완성하였다. Accordingly, the inventors of the present invention have completed the present invention by confirming that the extract of herbal medicine mixture containing the above-mentioned Hassuo, Manzan, Sansui, Sukjiro,
한편, 한국등록특허 제1198948호에는 숙지황을 함유하는 건강 음료 조성물, 한국등록특허 제1090284호에는 숙지황, 산수유 및 하수오가 함유된 홍삼 녹용 추출물, 한국등록특허 제1000528호에는 숙지황과 산수유를 함유하는 액상 추출물, 한국등록특허 제998225호에는 산수유와 산약을 함유하는 면역증강 조성물 등이 개시되어 있으며, 각 조성물들이 피로회복 효과가 있음이 개시되어 있지만, 상기 선행기술들의 조성물에 함유된 생약의 종류 또는 그 배합비율은 본 발명의 생약혼합물의 추출물에 함유된 것과 다르기에, 본 발명은 상기 선행기술들과는 기술구성이 다른 발명이라고 할 수 있다. On the other hand, Korean Patent No. 1198948 discloses a health drink composition containing Sulfuric Acid, Korean Patent No. 1090284 discloses extracts of red ginseng antler containing Sulfur Sulfur, Sodium Sulfate and Sulfuric Acid, and Korean Patent No. 1000528 discloses a liquid composition containing Sulfuric Acid and Sodium Sulphate Korean Patent Registration No. 998225 discloses an immunomodulating composition containing acidic milk and a herbal composition. It is disclosed that each composition has a fatigue recovery effect. However, the kind of herbal medicine contained in the composition of the prior art or the Since the compounding ratio is different from that contained in the extract of the herbal medicine mixture of the present invention, the present invention can be regarded as an invention having a different technical constitution from the above-mentioned prior arts.
본 발명의 목적은 생약혼합물을 유효성분으로 함유하는 피로회복용 조성물을 제공하는 데에 있으며, 자세하게는, 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물을 유효성분으로 함유하는 피로회복용 조성물을 제공하는 데에 있다. It is an object of the present invention to provide a fatigue-feeding composition comprising a herbal mixture as an active ingredient, and more particularly, to a fatigue-reducing composition containing an extract of a herbal medicine mixture containing a herbal mixture of Sasa, Mandarin, To provide a composition.
본 발명은 생약혼합물을 유효성분으로 함유하는 피로회복용 조성물에 관한 것으로서, 바람직하게는 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물을 유효성분으로 함유하는 피로회복용 조성물에 관한 것이다. TECHNICAL FIELD The present invention relates to a composition containing a herbal medicine as an active ingredient, and more particularly to a composition for the depression containing an extract of a herbal medicine mixture, which comprises desserts, manmunks, sour milk,
상기 생약혼합물에는 하수오 100 중량부를 기준으로, 만삼 50~200 중량부, 산수유 50~200 중량부, 숙지황 30~200 중량부 및 산약 10~50 중량부가 혼합될 수 있다. 50 to 200 parts by weight of mancham, 50 to 200 parts by weight of marine algae, 30 to 200 parts by weight of sorghum, and 10 to 50 parts by weight of marine algae can be mixed with the herbal mixture, based on 100 parts by weight of sodium chloride.
또한 상기 생약혼합물에는 하수오 100 중량부를 기준으로, 닭발 50~200 중량부, 구기자 50~200 중량부, 두충 50~200 중량부, 둥글레 10~50 중량부, 녹용 10~30 중량부, 생강 10~30 중량부, 대추 10~30 중량부, 감초 10~100 중량부 및 황기 10~50 중량부 중에서 선택되는 1종 이상의 생약이 혼합될 수 있다. Also, in the herbal medicine mixture, 50 to 200 parts by weight of chicken hair, 50 to 200 parts by weight of guinea pig, 50 to 200 parts by weight of guinea pig, 10 to 50 parts by weight of guinea pig, 10 to 30 parts by weight of ginger, 10 to 30 parts by weight of ginger, 10 to 30 parts by weight of jujube, 10 to 30 parts by weight of jujube, 10 to 100 parts by weight of licorice and 10 to 50 parts by weight of sulfur.
상기 생약혼합물의 추출물은, 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물을 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용매로 추출하여 제조할 수 있다.The extract of the crude drug mixture can be prepared by extracting a crude drug mixture containing Sasa, Manzan, Sansui, Sulfur and Sucrose with water, C1 to C4 lower alcohol or a mixed solvent thereof.
또한 본 발명은 생약혼합물을 유효성분으로 함유하는 피로회복용 조성물에 관한 것으로서, 바람직하게는 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물을 유효성분으로 함유하는 피로회복용 건강기능식품에 관한 것이다. In addition, the present invention relates to a composition containing a herbal medicine as an active ingredient, and more preferably to a health functional food containing an extract of a herbal medicine mixture, which comprises an extract of a herbal medicine, .
또다른 형태로서, 본 발명은, 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물의 제조방법을 제공하며, 바람직하게는, In another aspect, the present invention provides a method for preparing an extract of a crude drug mixture comprising Sasa, Manzan, Corn oil,
(1공정) 하수오 100 중량부, 만삼 50~200 중량부, 산수유 50~200 중량부, 숙지황 30~200 중량부 및 산약 10~50 중량부를 혼합하여 생약혼합물을 제조하는 단계; (1 step) preparing a herbal mixture by mixing 100 parts by weight of seaweed, 50-200 parts by weight of manchans, 50-200 parts by weight of marine oil, 30-200 parts by weight of Sulfuric Acid, and 10-50 parts by weight of Acid.
(2공정) 상기 1공정의 생약혼합물에, 상기 생약혼합물 전체 중량 1~10배의 추출용매를 혼합하여 70~130℃에서 1~10시간 동안 추출하는 단계; 및,(Step 2) Mixing the crude drug mixture of the above-mentioned one step with an extraction solvent having a total weight of 1 to 10 times the total weight of the crude drug mixture and extracting the mixture at 70 to 130 ° C for 1 to 10 hours; And
(3공정) 상기 2공정의 추출물의 고형분을 제거하고 여액을 수거하는 단계;를 통해 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물을 제조할 수 있다.(Step 3) Extracts of crude drug mixtures containing Hwaseo, Manchu, Sansui, Sukjiro, and Sangren can be prepared through the step of removing the solid content of the extracts of the two steps and collecting the filtrate.
이하 본 발명을 자세하게 설명한다. Hereinafter, the present invention will be described in detail.
상기 생약혼합물에 포함되는 하수오는 건조된 상태의 생약을 바로 이용할 수도 있으나, 하수오를 쌀뜨물에 0.5~2시간 동안 담그었다가 수증기로 10~60분 동안 찌고 1~5시간 동안 식히는 것을 5회 이상 반복하여 법제함으로서, 하수오의 약성을 낮추면서도 유효성분의 추출을 극대화시킬 수 있다. 하수오는 약성이 강해 법제하지 않고 바로 추출하게 되면 추출물을 투여하는 대상에게서 소화장애가 발생할 수도 있는데, 법제 후에는 약성이 순해지기 때문에 소화장애가 거의 나타나지 않는다. The raw sewage contained in the herbal mixture may be used directly in the dry state of the herbal medicine, but it is preferable that the pouring the sewage into the rice flour for 0.5 to 2 hours and then the steaming with steam for 10 to 60 minutes and the cooling for 1 to 5 hours By repeating the process, it is possible to maximize the extraction of active ingredients while lowering the mildew of the sewage. When the extract is directly extracted without being prescribed by law, the digestive disorder may occur in the subject to which the extract is administered. However, the digestive disorder hardly occurs due to the weakness after the law.
상기 생약혼합물에 포함되는 닭발은 생닭의 닭발 또는 냉동 닭발을 모두 사용할 수 있으며, 생닭의 닭발 또는 냉동 닭발을 바로 사용할 수도 있으나, 닭발 100 중량부 기준으로, 끓는 물 100~500 중량부에 소주 1~20 중량부 및 생강 1~20 중량부를 넣은 후 상기 닭발을 넣어 10~60분 동안 삶아 이용하는 것이 더 바람직하다. 상기 소주 대신 다른 주류를 이용할 수도 있다. 소주와 생강을 이용하여 닭발을 삶으면 닭 특유의 비린내와 기름기가 제거된다. 닭발에 포함된 콜라겐 성분은 피부에 활력을 주고 체내에 생동감을 주는 효과가 있다. The chicken broth included in the herbal mixture may be chicken broth or frozen chicken broth of raw chicken, and chicken broth or frozen chicken broth of raw chicken may be used immediately. However, 100 to 500 parts by weight of chicken broth may be added to 100 to 500 parts by weight of boiled water, 20 to 20 parts by weight of ginger and 1 to 20 parts by weight of ginger are added to the chicken broth and boiled for 10 to 60 minutes. Other liquor may be used instead of the soju. When boiled chicken boiled with shochu and ginger, the fish 's fishy smell and grease are removed. The collagen ingredient contained in the chicken feet gives vitality to the skin and gives a feeling of life to the body.
상기 생약혼합물의 추출물은 C1 내지 C4의 저급 알코올 또는 물과의 혼합용매를 이용할 경우에는 상기 추출물을 감압농축한 농축물 또는 이의 건조물 형태로 사용할 수 있다. 또한, 물을 이용하여 추출하였을 경우에는 고형분을 제거한 여액을 바로 이용할 수 있으며, 이를 감압농축한 농축물 또는 이의 건조물 형태로도 사용할 수 있다. The extract of the crude drug mixture may be used in the form of a concentrate obtained by concentrating the extract at a reduced pressure or a dried product thereof when a C1 to C4 lower alcohol or a mixed solvent with water is used. In addition, in the case of extracting with water, the filtrate from which the solid content has been removed can be immediately used, and it can be used in the form of a concentrated product or a dried product thereof.
상기 생약혼합물의 추출물은 상법에 따라, 유기용매(알코올, 에테르, 아세톤 등)에 의한 추출, 헥산과 물의 분배, 칼럼크로마토그래피에 의한 방법 등, 식물체 성분의 분리 추출에 이용되는 공지의 방법을 단독 또는 적합하게 조합한 방법을 이용하여 분획 또는 정제하여 사용할 수 있다. The extract of the crude drug mixture may be isolated by known methods used for separation and extraction of plant components, such as extraction with an organic solvent (alcohol, ether, acetone, etc.), partition with hexane and water, Or may be fractionated or purified by a suitable combination method.
상기 크로마토그래피는 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 엘에이취-20 컬럼 크로마토그래피(LH-20 column chromatography), 이온교환수지 크로마토그래피(ion exchange resin chromatography), 중압 액체 크로마토그래피(medium pressure liquid chromatography), 박층 크로마토그래피(TLC; thin layer chromatography), 실리카겔 진공 액체 크로마토그래피(silica gel vacuum liquid chromatography) 및 고성능 액체 크로마토그래피(high performance liquid chromatography) 중에서 선택될 수 있다. The chromatography can be carried out using silica gel column chromatography, LH-20 column chromatography, ion exchange resin chromatography, medium pressure liquid chromatography chromatography, thin layer chromatography (TLC), silica gel vacuum liquid chromatography, and high performance liquid chromatography.
또한, 본 발명은 상기 생약혼합물의 추출물을 유효성분으로 함유하는 피로회복용 약학 조성물을 제공한다. 상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 생약혼합물의 추출물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. In addition, the present invention provides a pharmaceutical composition containing a pharmaceutical composition containing the extract of the crude drug mixture as an active ingredient. The pharmaceutical compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to conventional methods. Examples of carriers, excipients and diluents that can be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose, Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학 조성물의 투여량은 치료받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은, 생약혼합물의 농축건조물이 포함된 조성물 기준으로, 0.01㎎/㎏/일 내지 대략 2000㎎/㎏/일의 범위이다. 더 바람직한 투여량은 1㎎/㎏/일 내지 500㎎/㎏/일이다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The dosage of the pharmaceutical composition of the present invention will depend on the age, sex, body weight of the subject to be treated, the particular disease or condition to be treated, the severity of the disease or condition, the route of administration and the judgment of the prescriber. Dosage determinations based on these factors are within the level of ordinary skill in the art and generally the dosage ranges from 0.01 mg / kg / day to approximately 2000 mg / kg / day, based on the composition comprising the concentrated dried product of the herbal mixture. A more preferable dosage is 1 mg / kg / day to 500 mg / kg / day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 약학 조성물은 쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여될 수 있다. 본 발명의 화합물은 독성 및 부작용이 거의 없으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있는 약제이다. The pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection. Since the compound of the present invention has little toxicity and side effects, it can be safely used even for long-term administration for preventive purposes.
또한, 본 발명은 상기 생약혼합물의 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 함유하는 피로회복용 건강기능식품을 제공한다. 본 발명의 건강기능식품은 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함하며, 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능성식품류 등이 있다. In addition, the present invention provides a health food containing fatigue containing an extract of the herbal medicine mixture and a pharmaceutically acceptable food-aid additive. The health functional food of the present invention includes forms such as tablets, capsules, pills, and liquids. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamins , And health functional foods.
한편, 본 발명의 생약혼합물의 추출물이 함유된 피로회복용 조성물 또는 건강기능식품은 파우치 형태에 멸균 포장되어 복용하기 용이한 형태로서 제공될 수도 있다.Meanwhile, the fatigue-related composition or health functional food containing the extract of the herbal medicine mixture of the present invention may be provided as a form which is easily sterilized and packaged in a pouch form.
본 발명은 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물을 함유하는 조성물에 관한 것으로서, 상기 생약혼합물의 추출물을 함유하는 조성물은 운동기능의 유지능력, 피로회복 개선 효과가 우수하여, 수험생, 직장인, 회복기 환자들의 피로회복용 조성물 또는 건강기능식품으로 용이하게 사용 가능하다. The present invention relates to a composition containing an extract of a crude drug mixture comprising Hassuo, Manzan, Sansui, Sulfur and Sulfur, wherein the composition containing the extract of the crude drug mixture is excellent in the ability to maintain a motor function and to improve fatigue recovery , A candidate, a worker, a convalescent patient in a recovery period, or a health functional food.
도 1은 본 발명의 생약혼합물의 추출물의 제조공정을 나타내는 순서도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow chart showing a process for producing an extract of a crude drug mixture of the present invention. FIG.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지고, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다. Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, the intention is to provide an exhaustive, complete, and complete disclosure of the principles of the invention to those skilled in the art.
<실시예 1. 하수오, 만삼, 산수유, 숙지황 및 산약을 포함하는 생약혼합물의 추출물 제조>EXAMPLES Example 1. Preparation of Extracts of Herbal Drugs Containing Sasa, Mandarin, Sansui Oil,
하기 표 1의 생약혼합물을 물 6kg과 혼합하여 120℃에서 9시간 동안 한약 추출기를 이용하여 추출하였고, 고형분을 제거하여 각각의 생약혼합물의 추출물을 얻었다. 이 때 생약혼합물의 총 중량은 850g으로 통일하였다. The crude drug mixture of Table 1 below was mixed with 6 kg of water and extracted with a herbal extractor at 120 ° C for 9 hours. The solid content was removed to obtain an extract of each herbal mixture. At this time, the total weight of the crude drug mixture was unified to 850 g.
이 때, 상기 하수오는 쌀뜨물에 1시간 동안 담그었다가 수증기로 20분 찌고, 2시간 식히는 과정을 5회 반복하여 법제하여 사용하였고, 생약혼합물에 이용될 닭발은 냉동된 닭발을 해동시키고, 닭발 2kg당 끓는 물 5kg에 소주 100g, 생강 200g을 넣은 후 상기 해동된 닭발을 20분 삶아서 건져낸 것을 사용하였다(삶은 물은 버리고 닭발은 찬물에 2번 헹구어 식힌 후 생약 추출에 이용함). At this time, the poultry was immersed in rice cakes for 1 hour, steamed for 20 minutes with water vapor and cooled for 2 hours, and used 5 times repeatedly. The broiler chickens used in the herbal mixture were thawed frozen chicken legs, 100 g of soju and 200 g of ginger were added to 5 kg of boiling water per 2 kg, and then the defrosted chicken broth was boiled for 20 minutes (boiled water was discarded and chicken broth was used for cold extraction after cold rinsing twice).
<< 비교예Comparative Example 1. 비교대상 추출물의 제조> 1. Preparation of comparative extracts>
실시예 1과 동일한 방법으로 생약혼합물의 추출물을 제조하되, 생약의 혼합 조건은 하기 표 2를 참고하여 비교대상 추출물을 제조하였다.An extract of the crude drug mixture was prepared in the same manner as in Example 1, and the extract for comparison was prepared by referring to Table 2 below.
<< 실험예Experimental Example 1. 수영운동 테스트에 따른 신진대사 개선 효과 확인> 1. Checking the improvement of metabolism by swimming exercise test>
깊이 1m 이상의 수조를 사용하여 수조를 미지근한 온도(30℃ 정도)로 조절하였다. 각 군당 7마리의 스프라그 돌리계 수컷 흰쥐(약 200g정도)에게 본 발명 생약 혼합 추출물의 동결건조물을 200㎎/㎏씩 경구투여하였다. 경구투여 30분 후 꼬리에 의한 부력이용을 방지하기 위하여, 10g의 금속추를 흰쥐의 꼬리에 부착하여 물속에 잠기게 하였고, 흰쥐를 수조에 넣어 물 위에서 가라앉지 않고 지속적으로 수영을 하며 떠 있는 시간들을 확인하였다. 흰쥐의 수영능력 상실의 판정은 흰쥐의 몸 전체가 수면 아래로 완전히 잠기는 순간으로 하였으며, 흰쥐들의 수영시간은 평균값으로 하기 표 3에 기재하였다. The water tank was adjusted to a lukewarm temperature (about 30 ° C) using a water tank having a depth of 1 m or more. The lyophilized extract of the present invention was orally administered at a dose of 200 mg / kg to seven Sprague Dawley male rats (about 200 g) per group. After 30 minutes of oral administration, 10 g of metal weight was attached to the tail of the rat to immerse it in the water to prevent buoyancy by the tail, and the rat was kept in a water bath, immersed in water, Respectively. The determination of the loss of swimming ability of the rat was made at the moment when the entire body of the rat was completely submerged in the water, and the swimming time of the rats was shown in Table 3 as an average value.
하기 표 3을 참고하면, 본 발명의 실시예 1의 생약 추출물을 투여했던 흰쥐의 수영시간이 비교군 추출물을 투여한 흰쥐에 비해 수영시간이 현저하게 긴 것으로 확인되었으며, 이로 인해 실시예 1의 생약 추출물이 흰쥐들의 피로회복도를 개선시켜 신진대사가 증가된 상태임을 예상할 수 있었다.As shown in the following Table 3, it was found that the swimming time of the rat administered with the herbal medicine extract of Example 1 of the present invention was significantly longer than that of the rats administered with the comparative group extract, The extracts could be expected to improve the metabolism of the rat by improving the fatigue hallway.
<< 실험예Experimental Example 2. 피로회복 개선 효과 확인> 2. Confirmation of improvement of fatigue recovery>
2012년 9월부터 실시예 1 및 비교예 1의 각 추출물 별로 7명씩 10~60대의 남녀노소에게 상기 추출물을 20일간, 매일 하루 3번 110㎖씩 식후 2시간 후에 복용하게 하였으며, 20일간의 복용 후, 피로감 개선 정도를 하기 표 4에 5점 타점법(5점 : 아주우수함, 4점 : 우수함, 3점 : 보통, 2점 : 나쁨, 1점 : 아주나쁨)으로 나타내게 하였다. 이를 위해, 숙면 효과, 무기력감 개선 효과, 전체적인 피로감 개선 효과 등을 확인하였다. From Sep. 2012, the extracts were administered to 10- to 60-year-olds for 7 days for each extract of Example 1 and Comparative Example 1, for 2 days after a meal for 20 days, three times a day for 3 days, and 20 days The degree of improvement in fatigue was expressed by the 5-point spot method (5 points: excellent, 4 points: excellent, 3 points: normal, 2 points: poor, 1 point: very poor) in Table 4 below. For this purpose, sleeping effect, helplessness improvement effect, and overall fatigue improvement effect were confirmed.
조건
Condition
숙면 효과
Sleep effect
개선 효과Helplessness
Improvement effect
피로감
개선 효과Overall
Fatigue
Improvement effect
표 4를 참고하면, 본 발명의 생약혼합물의 추출물은 숙면 효과를 가져오며, 무기력을 감소시키는 효과가 있었으며, 전체적인 피로감을 개선시키는 효과가 아주 우수하였다.As shown in Table 4, the extract of the herbal medicine mixture of the present invention has a sleeping effect, an effect of reducing the helminth, and an excellent effect of improving the overall fatigue.
<실험예 3. 독성실험> <Experimental Example 3> Toxicity test>
실험예 3-1. 급성독성Experimental Example 3-1. Acute toxicity
본 발명의 실시예 1-1 및 1-8의 생약혼합물의 추출물(동결건조물)을 단기간에 과량을 섭취하였을 때 급성적(24시간 이내)으로 동물체내에 미치는 독성을 조사하고, 치사율을 결정하기 위하여 본 실험을 수행하였다. 일반적인 마우스인 ICR 마우스 계통 30마리를 대조군과 실험군에 각각 10마리씩 배정하였다. 대조군에는 PEG-400/tween-80/EtOH(8/1/1, v/v/v) 만을 투여하고, 실험군은 본 발명의 실시예 1-1 및 1-8의 생약혼합물의 추출물을 상기 PEG-400/tween-80/EtOH(8/1/1, v/v/v)에 녹여 각각 경구투여하였다. 투여 24시간 후에 각각의 치사율을 조사한 결과, 대조군과 2g/㎏/day 농도의 본 발명의 실시예 1-1 및 1-8의 생약혼합물의 추출물을 투여한 실험군에서 마우스가 모두 생존하는 것으로 확인되었다.The toxicity of the extracts (lyophilisates) of the herbal preparations of Examples 1-1 and 1-8 of the present invention to the animal body in an acute manner (within 24 hours) when an excessive amount of the extracts were taken in a short period of time and the mortality rate was determined This experiment was performed. Twenty mice of the general mouse ICR mouse line were assigned to each of the control and experimental groups. In the control group, only PEG-400 / tween-80 / EtOH (8/1/1, v / v / v) was administered and in the experimental group, the extract of the crude drug mixture of Examples 1-1 and 1-8 of the present invention, -400 / tween-80 / EtOH (8/1/1, v / v / v). As a result of examining the mortality rates after 24 hours of administration, it was confirmed that all the mice survived in the control group and in the experimental group administered with the herbal mixture extract of Examples 1-1 and 1-8 of the present invention at the concentration of 2 g / kg / day .
실험예 3-2. 실험군 및 대조군의 장기 및 조직 독성 실험Experimental Example 3-2. Organ organs toxicity test in experimental group and control group
장기 독성 실험은 본 발명의 실시예 1-1 및 1-8의 생약혼합물의 추출물(동결건조물)을 각 농도로 8주 동안 C57BL/6J 마우스(각 군당 10마리)에 투여하여 실험하였다. 동물의 각 장기(조직)에 미치는 영향을 조사하기 위하여 본 발명의 실시예 1-1 및 1-8의 생약혼합물의 추출물을 투여한 실험군과 PEG-400/tween-80/EtOH(8/1/1, v/v/v)만을 투여한 대조군의 동물들로부터 8주 후 혈액을 채취하여 GPT(glutamate-pyruvate transferase) 및 BUN(blood urea nitrogen)의 혈액 내 농도를 Select E(Vital Scientific NV, Netherland) 기기를 이용하여 측정하였다. 그 결과, 간독성과 관계있는 것으로 알려진 GPT와 신장독성과 관계있는 것으로 알려진 BUN의 경우, 대조군과 비교하여 실험군은 별다른 차이를 보이지 않았다. 또한, 각 동물로부터 간과 신장을 절취하여 통상적인 조직절편 제작과정을 거쳐 광학현미경으로 조직학적 관찰을 시행하였으며 모든 조직에서 특이한 이상이 관찰되지 않았다. In the long-term toxicity test, the extracts (lyophilisates) of the herbal mixtures of Examples 1-1 and 1-8 of the present invention were administered to C57BL / 6J mice (10 rats per group) for 8 weeks at each concentration. In order to investigate the effects on the organs (tissues) of animals, the experimental group to which the extract of crude drug mixture of Examples 1-1 and 1-8 of the present invention and the PEG-400 / tween-80 / After 8 weeks from the control group, the blood concentration of glutamate-pyruvate transferase (GPT) and blood urea nitrogen (BUN) was measured by Select E (Vital Scientific NV, Netherland ) Instrument. As a result, GPT, which is known to be related to hepatotoxicity, and BUN, which is known to be related to renal toxicity, showed no significant difference compared to the control group. In addition, liver and kidney were cut from each animal, followed by a general tissue section preparation, histological observation with an optical microscope, and no abnormalities were observed in all tissues.
<제제예 1. 약학적 제제>≪ Formulation Example 1 >
1-1. 정제의 제조1-1. Manufacture of tablets
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물) 200g을 락토오스 175.9g, 감자전분 180g 및 콜로이드성 규산 32g과 혼합하였다. 이 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄해서 14 메쉬체를 통과시켰다. 이것을 건조시키고 여기에 감자전분 160g, 활석 50g 및 스테아린산 마그네슘 5g을 첨가해서 얻은 혼합물을 정제로 만들었다. 200g of the extract (lyophilized product) of the crude drug mixture of Examples 1-8 of the present invention was mixed with 175.9g of lactose, 180g of potato starch and 32g of colloidal silicic acid. To this mixture was added a 10% gelatin solution, which was pulverized and passed through a 14-mesh sieve. This was dried, and a mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was made into tablets.
1-2. 주사액제의 제조1-2. Injection preparation
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물) 1g, 염화나트륨 0.6g 및 아스코르브산 0.1g을 증류수에 용해시켜서 100㎖를 만들었다. 이 용액을 병에 넣고 20℃에서 30분간 가열하여 멸균시켰다.1 g of the herbal mixture extract (lyophilized product) of Example 1-8 of the present invention, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml. This solution was placed in a bottle and sterilized by heating at 20 DEG C for 30 minutes.
<제제예 2. 식품 제조><Formulation Example 2: Food Preparation>
2-1. 조리용 양념의 제조2-1. Manufacture of cooking seasonings
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물)을 조리용 양념에 1 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다.The livestock mixture extract (lyophilized product) of Examples 1-8 of the present invention was added to the cooking seasoning at 1 wt% to prepare a cooking sauce for health promotion.
2-2. 밀가루 식품의 제조2-2. Manufacture of flour food products
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물)을 밀가루에 0.1 중량%로 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.(Lyophilized product) of the herbal mixture of Examples 1-8 of the present invention was added to wheat flour at 0.1 wt%, and bread, cake, cookies, crackers and noodles were prepared using the mixture to prepare health promotion foods Respectively.
2-3. 스프 및 육즙(gravies)의 제조2-3. Manufacture of soups and gravies
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물)을 스프 및 육즙에 0.1 중량%로 첨가하여 건강 증진용 수프 및 육즙을 제조하였다.The health enhancing soup and the juice were prepared by adding the extract (lyophilized product) of the herbal mixture of Examples 1-8 of the present invention to the soup and juice at 0.1 wt%.
2-4. 유제품(dairy products)의 제조2-4. Manufacture of dairy products
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물)을 우유에 0.1 중량%로 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.The lyophilized product extract (lyophilized product) of Examples 1-8 of the present invention was added to milk in an amount of 0.1% by weight, and various dairy products such as butter and ice cream were prepared using the milk.
2-5. 야채주스 제조2-5. Vegetable juice manufacturing
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물) 0.5g을 토마토주스 또는 당근주스 1,000㎖에 가하여 건강 증진용 야채주스를 제조하였다.0.5 g of the herbal mixture extract (lyophilized product) of Examples 1-8 of the present invention was added to 1,000 ml of tomato juice or carrot juice to prepare vegetable juice for health promotion.
2-6. 과일주스 제조2-6. Manufacture of fruit juice
본 발명의 실시예 1-8의 생약혼합물의 추출물(동결건조물) 0.1g을 사과주스 또는 포도주스 1,000㎖에 가하여 건강 증진용 과일주스를 제조하였다.
0.1 g of the extract (lyophilized product) of the crude drug mixture of Example 1-8 of the present invention was added to 1,000 ml of apple juice or grape juice to prepare health promotion fruit juice.
Claims (10)
상기 생약혼합물에는 하수오 100 중량부를 기준으로, 닭발 50~200 중량부, 구기자 50~200 중량부, 두충 50~200 중량부, 둥글레 10~50 중량부, 녹용 10~30 중량부, 생강 10~30 중량부, 대추 10~30 중량부, 감초 10~100 중량부 및 황기 10~50 중량부에서 선택되는 1종 이상의 생약이 혼합되는 것을 특징으로 하는 피로회복용 조성물.In the first aspect,
The herbal medicine mixture contains 50 to 200 parts by weight of chicken hair, 50 to 200 parts by weight of guinea pig, 50 to 200 parts by weight of guinea pig, 10 to 50 parts by weight of guinea pig, 10 to 30 parts by weight of ginger, 10 to 30 parts by weight of ginger, 10 to 30 parts by weight of jujube, 10 to 100 parts by weight of licorice, and 10 to 50 parts by weight of sulfur.
상기 생약혼합물의 추출물은, 하수오 100 중량부, 만삼 50~200 중량부, 산수유 50~200 중량부, 숙지황 30~200 중량부 및 산약 10~50 중량부를 포함하는 생약혼합물을 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용매로 추출하여 제조하는 것을 특징으로 하는 피로회복용 조성물.The method according to claim 1,
Wherein the herbal mixture comprises 100 to 50 parts by weight of water, 50 to 200 parts by weight of mannitol, 50 to 200 parts by weight of citronellal oil, 30 to 200 parts by weight of Sulfuric acid, A lower alcohol, or a mixed solvent thereof.
상기 생약혼합물에는 하수오 100 중량부를 기준으로, 닭발 50~200 중량부, 구기자 50~200 중량부, 두충 50~200 중량부, 둥글레 10~50 중량부, 녹용 10~30 중량부, 생강 10~30 중량부, 대추 10~30 중량부, 감초 10~100 중량부 및 황기 10~50 중량부에서 선택되는 1종 이상의 생약이 혼합되는 것을 특징으로 하는 피로회복용 건강기능식품.6. The method of claim 5,
The herbal medicine mixture contains 50 to 200 parts by weight of chicken hair, 50 to 200 parts by weight of guinea pig, 50 to 200 parts by weight of guinea pig, 10 to 50 parts by weight of guinea pig, 10 to 30 parts by weight of ginger, 10 to 30 parts by weight of ginger, 10 to 30 parts by weight of jujube, 10 to 100 parts by weight of licorice, and 10 to 50 parts by weight of sulfur.
상기 생약혼합물의 추출물은, 하수오 100 중량부, 만삼 50~200 중량부, 산수유 50~200 중량부, 숙지황 30~200 중량부 및 산약 10~50 중량부를 포함하는 생약혼합물을 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용매로 추출하여 제조하는 것을 특징으로 하는 피로회복용 건강기능식품.6. The method of claim 5,
Wherein the herbal mixture comprises 100 to 50 parts by weight of water, 50 to 200 parts by weight of mannitol, 50 to 200 parts by weight of citronellal oil, 30 to 200 parts by weight of Sulfuric acid, A low-alcohol, or a mixed solvent thereof.
(2공정) 상기 1공정의 생약혼합물에, 상기 생약혼합물 전체 중량 1~10배의 추출용매를 혼합하여 70~130℃에서 1~10시간 동안 추출하는 단계; 및,
(3공정) 상기 2공정의 추출물의 고형분을 제거하고 여액을 수거하는 단계;
를 포함하는 하수오, 만삼, 산수유, 숙지황 및 산약을 함유하는 생약혼합물의 추출물 제조방법. (1 step) preparing a herbal mixture by mixing 100 parts by weight of seaweed, 50-200 parts by weight of manchans, 50-200 parts by weight of marine oil, 30-200 parts by weight of Sulfuric Acid, and 10-50 parts by weight of Acid.
(Step 2) Mixing the crude drug mixture of the above-mentioned one step with an extraction solvent having a total weight of 1 to 10 times the total weight of the crude drug mixture and extracting the mixture at 70 to 130 ° C for 1 to 10 hours; And
(Step 3) removing the solid content of the extract of the two steps and collecting the filtrate;
Wherein the extract is prepared from a mixture of herbal medicines containing at least one selected from the group consisting of seaweed, ginseng, corn oil,
2공정의 추출용매는 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용매에서 선택되는 것을 특징으로 하는 생약혼합물의 추출물 제조방법.
10. The method of claim 9,
Wherein the extraction solvent of step 2 is selected from water, C1 to C4 lower alcohols or a mixed solvent thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130068969A KR101513240B1 (en) | 2013-06-17 | 2013-06-17 | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130068969A KR101513240B1 (en) | 2013-06-17 | 2013-06-17 | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140146378A KR20140146378A (en) | 2014-12-26 |
KR101513240B1 true KR101513240B1 (en) | 2015-04-21 |
Family
ID=52675642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130068969A Expired - Fee Related KR101513240B1 (en) | 2013-06-17 | 2013-06-17 | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101513240B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101988959B1 (en) | 2019-05-13 | 2019-06-14 | 주식회사 한미양행 | Stress relieving or anti-fatigue composition containing enzymatic treatment white grub |
KR20200036715A (en) | 2019-07-02 | 2020-04-07 | 콜마비앤에이치 주식회사 | Composition for improving fatigue recovery or exercise performance comprising angelica gigas nakai extract, cnidium officinale makino extract and paeonia japonica extract |
KR20220151393A (en) | 2021-05-06 | 2022-11-15 | 도영복 | Health functional tea composition for stress relief containing ginseng |
-
2013
- 2013-06-17 KR KR1020130068969A patent/KR101513240B1/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
J Korean Soc Food Sci Nutr, Vol.36, No.6, pp.678-682 (2007)* |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101988959B1 (en) | 2019-05-13 | 2019-06-14 | 주식회사 한미양행 | Stress relieving or anti-fatigue composition containing enzymatic treatment white grub |
KR20200036715A (en) | 2019-07-02 | 2020-04-07 | 콜마비앤에이치 주식회사 | Composition for improving fatigue recovery or exercise performance comprising angelica gigas nakai extract, cnidium officinale makino extract and paeonia japonica extract |
KR20220151393A (en) | 2021-05-06 | 2022-11-15 | 도영복 | Health functional tea composition for stress relief containing ginseng |
Also Published As
Publication number | Publication date |
---|---|
KR20140146378A (en) | 2014-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103141832A (en) | Black fungus diet therapy health-preserving diet and preparation method thereof | |
KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
KR101419463B1 (en) | Herbal composition for prevention and treatment of hepatic disease | |
KR100771524B1 (en) | Liver function improvement composition containing mixed herbal extract as active ingredient | |
KR102080410B1 (en) | Composition for Preventing, Treating or Improving of Andropause Syndrome Comprising Elderberry Extracts | |
KR101474125B1 (en) | Composition comprising complex extract of Astragalus membranaceus BUNGE, Saposhnikovia divaricata Schiskin, Ostericum koreanum Maximowicz, Scutellaria baicalensis Georgi and Atractylodes japonica Koidz for preventing or treating asthma, bronchitis or pneumonia | |
CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
KR20150105616A (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
KR101513240B1 (en) | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds | |
KR102672925B1 (en) | Composition for promoting growth of height comprising extracts of Cervus Parvum Cornu | |
KR101394358B1 (en) | Health composition relieving alcohol hangover | |
KR101647917B1 (en) | Chestnut medicinal wine having extract of stachys sieboldii and methods for manufacturing thereof | |
KR100830553B1 (en) | Inflammation-related diseases prevention and treatment compositions | |
KR102151011B1 (en) | Composition for preventing, improving or treating liver disease comprising fermented liquor of aged sprout ginseng extract as effective component | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR20200061285A (en) | Food Composition for blood circulation and for Preventing blood vessel disease Comprising Extract of Galangal | |
KR102217732B1 (en) | Composition for preventing and improving the development of premature pseudo-breast | |
KR101544000B1 (en) | A composition comprising extracts of herbal mixture having skin whitening effect | |
KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR101154031B1 (en) | Composition for Antifati gue containin g herbal mixture extract as in gredient compounds | |
KR100888068B1 (en) | Obesity Inhibitory Composition | |
JP6063499B2 (en) | Pharmaceutical composition for prevention and treatment of male infertility containing dough yellow, eggplant, agarwood, persimmon, a mixture of ginseng and honey as active ingredients | |
KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
KR102494072B1 (en) | Composition for improving or preventing depression comprising herbal extracts and method for preparing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20130617 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140627 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20150112 |
|
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20150413 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20150413 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PC1903 | Unpaid annual fee | ||
PR0401 | Registration of restoration |
Patent event code: PR04011E01D Patent event date: 20181129 Comment text: Registration of Restoration |
|
PR1001 | Payment of annual fee |
Payment date: 20181129 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190218 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20190218 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20200314 Start annual number: 6 End annual number: 6 |
|
PC1903 | Unpaid annual fee |